PMC7506050_01
Flow chart of the care process for the presented cases. LAAO, left atrial appendage occlusion; TEE, transesophageal echocardiogram; DRT, device-related thrombosis; dual antiplatelet, 100 mg of aspirin combined with 75 mg of clopidogrel; mono antiplatelet, 100 mg of aspirin only.
fphar-11-563920-g001.jpg
PMC7506050_04_fphar-11-563920-g001.jpg
f1
The routine follow-up TEE for the LAAC device position after 2 months revealed thrombus on the surface of the occluder ( Figure 2 , d1).
Left atrial appendage occlusion-related thrombus anticoagulated with dabigatran. (a) TEE 2-dimensional view displayed thrombosis (2.59 cm x 1.67 cm) on the surface of the occluder (a1). After six weeks of warfarin treatment, a regression of the thrombosis was shown (1.27 cm x 0.605 cm), which confirmed the diagnosis of device-related thrombosis (a2). (b) TEE revealed a thrombus (0.713 cm x 0.621 cm) on the anterolateral surface of the occluder (b1) and the total disappearance of the thrombus after initiation of anticoagulation therapy with rivaroxaban (b2). (c) TEE check-up revealed abnormal hemodynamics in the LAA, identified as thrombosis (0.713 cm x 0.621 cm) (c1), and total elimination of DRT after 3 months following anticoagulation treatment with warfarin (c2). (d) TEE revealed a thrombus (0.661 cmx0.227 cm) on the surface of the occluder (d1) and the total disappearance of the thrombus after the initiation of anticoagulation therapy with warfarin (d2). Red arrows indicate the thrombosis.
fphar-11-563920-g002.jpg
PMC7506050_04_fphar-11-563920-g002.jpg
f2
The routine follow-up TEE for the LAAC device position after 2 months revealed thrombus on the surface of the occluder ( Figure 2 , d1). TEE scheduled for 8 weeks later. TEE check-ups later revealed the total disappearance of the abnormal thrombosis with the final diagnosis refined as DRT ( Figure 2 , d2).
PMC7506050_02
Flow chart of the care process for the presented cases. LAAO, left atrial appendage occlusion; TEE, transesophageal echocardiogram; DRT, device-related thrombosis; dual antiplatelet, 100 mg of aspirin combined with 75 mg of clopidogrel; mono antiplatelet, 100 mg of aspirin only.
fphar-11-563920-g001.jpg
PMC7506050_04_fphar-11-563920-g001.jpg
f1
The routine follow-up TEE for the LAAC device position after 2 months revealed thrombus on the surface of the occluder ( Figure 2 , d1).
Left atrial appendage occlusion-related thrombus anticoagulated with dabigatran. (a) TEE 2-dimensional view displayed thrombosis (2.59 cm x 1.67 cm) on the surface of the occluder (a1). After six weeks of warfarin treatment, a regression of the thrombosis was shown (1.27 cm x 0.605 cm), which confirmed the diagnosis of device-related thrombosis (a2). (b) TEE revealed a thrombus (0.713 cm x 0.621 cm) on the anterolateral surface of the occluder (b1) and the total disappearance of the thrombus after initiation of anticoagulation therapy with rivaroxaban (b2). (c) TEE check-up revealed abnormal hemodynamics in the LAA, identified as thrombosis (0.713 cm x 0.621 cm) (c1), and total elimination of DRT after 3 months following anticoagulation treatment with warfarin (c2). (d) TEE revealed a thrombus (0.661 cmx0.227 cm) on the surface of the occluder (d1) and the total disappearance of the thrombus after the initiation of anticoagulation therapy with warfarin (d2). Red arrows indicate the thrombosis.
fphar-11-563920-g002.jpg
PMC7506050_04_fphar-11-563920-g002.jpg
f2
The routine follow-up TEE for the LAAC device position after 2 months revealed thrombus on the surface of the occluder ( Figure 2 , d1). TEE scheduled for 8 weeks later. TEE check-ups later revealed the total disappearance of the abnormal thrombosis with the final diagnosis refined as DRT ( Figure 2 , d2).
PMC7506050_03
Flow chart of the care process for the presented cases. LAAO, left atrial appendage occlusion; TEE, transesophageal echocardiogram; DRT, device-related thrombosis; dual antiplatelet, 100 mg of aspirin combined with 75 mg of clopidogrel; mono antiplatelet, 100 mg of aspirin only.
fphar-11-563920-g001.jpg
PMC7506050_04_fphar-11-563920-g001.jpg
f1
The routine follow-up TEE for the LAAC device position after 2 months revealed thrombus on the surface of the occluder ( Figure 2 , d1).
Left atrial appendage occlusion-related thrombus anticoagulated with dabigatran. (a) TEE 2-dimensional view displayed thrombosis (2.59 cm x 1.67 cm) on the surface of the occluder (a1). After six weeks of warfarin treatment, a regression of the thrombosis was shown (1.27 cm x 0.605 cm), which confirmed the diagnosis of device-related thrombosis (a2). (b) TEE revealed a thrombus (0.713 cm x 0.621 cm) on the anterolateral surface of the occluder (b1) and the total disappearance of the thrombus after initiation of anticoagulation therapy with rivaroxaban (b2). (c) TEE check-up revealed abnormal hemodynamics in the LAA, identified as thrombosis (0.713 cm x 0.621 cm) (c1), and total elimination of DRT after 3 months following anticoagulation treatment with warfarin (c2). (d) TEE revealed a thrombus (0.661 cmx0.227 cm) on the surface of the occluder (d1) and the total disappearance of the thrombus after the initiation of anticoagulation therapy with warfarin (d2). Red arrows indicate the thrombosis.
fphar-11-563920-g002.jpg
PMC7506050_04_fphar-11-563920-g002.jpg
f2
The routine follow-up TEE for the LAAC device position after 2 months revealed thrombus on the surface of the occluder ( Figure 2 , d1). TEE scheduled for 8 weeks later. TEE check-ups later revealed the total disappearance of the abnormal thrombosis with the final diagnosis refined as DRT ( Figure 2 , d2).
PMC7506050_04
Flow chart of the care process for the presented cases. LAAO, left atrial appendage occlusion; TEE, transesophageal echocardiogram; DRT, device-related thrombosis; dual antiplatelet, 100 mg of aspirin combined with 75 mg of clopidogrel; mono antiplatelet, 100 mg of aspirin only.
fphar-11-563920-g001.jpg
PMC7506050_04_fphar-11-563920-g001.jpg
f1
The routine follow-up TEE for the LAAC device position after 2 months revealed thrombus on the surface of the occluder ( Figure 2 , d1).
Left atrial appendage occlusion-related thrombus anticoagulated with dabigatran. (a) TEE 2-dimensional view displayed thrombosis (2.59 cm x 1.67 cm) on the surface of the occluder (a1). After six weeks of warfarin treatment, a regression of the thrombosis was shown (1.27 cm x 0.605 cm), which confirmed the diagnosis of device-related thrombosis (a2). (b) TEE revealed a thrombus (0.713 cm x 0.621 cm) on the anterolateral surface of the occluder (b1) and the total disappearance of the thrombus after initiation of anticoagulation therapy with rivaroxaban (b2). (c) TEE check-up revealed abnormal hemodynamics in the LAA, identified as thrombosis (0.713 cm x 0.621 cm) (c1), and total elimination of DRT after 3 months following anticoagulation treatment with warfarin (c2). (d) TEE revealed a thrombus (0.661 cmx0.227 cm) on the surface of the occluder (d1) and the total disappearance of the thrombus after the initiation of anticoagulation therapy with warfarin (d2). Red arrows indicate the thrombosis.
fphar-11-563920-g002.jpg
PMC7506050_04_fphar-11-563920-g002.jpg
f2
The routine follow-up TEE for the LAAC device position after 2 months revealed thrombus on the surface of the occluder ( Figure 2 , d1). TEE scheduled for 8 weeks later. TEE check-ups later revealed the total disappearance of the abnormal thrombosis with the final diagnosis refined as DRT ( Figure 2 , d2).